


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
APPROVAL OF CLINICAL TRIAL FOR TQB3015
“ATR KINASE INHIBITOR” TABLET

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the TQB3015 “ATR kinase inhibitor” tablet developed by the Group has been approved by the National Medical Products Administration of China to commence clinical trials for the treatment of advanced malignant tumors.

In recent years, the overall five-year survival rate of cancers in China has improved to a certain extent, but there is still a lack of effective treatments for refractory tumors, such as advanced gastric cancer, pancreatic cancer, esophageal cancer, small cell lung cancer and triple-negative breast cancer as well as patients with drug resistance to platinum and PARP (poly ADP-ribose polymerase) inhibitors or immune checkpoint inhibitors, etc. There is an urgent need to develop novel anti-tumor drugs to meet such clinical needs. ATR kinase inhibitors are expected to bring a new treatment option for patients with drug resistance or refractory tumors, and currently there is no product of the same kind available in the global market.

TQB3015 developed by the Group is a small molecule inhibitor with ATR kinase as the targeted agent to induce cell cycle arrest and inhibit the ATR kinase-mediated repairing pathway by inhibiting the phosphorylation of cell cycle checkpoint kinase CHK1, thereby blocking the DNA damage response of tumor cells, and achieving the effect of “synthetic lethality” to kill tumor cells efficiently.

Preclinical studies demonstrated that TQB3015 tablet has good anti-tumor activity and safety, and in addition, TQB3015 tablet has good potential for use in combination with common chemotherapy, radiotherapy and immunotherapy, which is expected to bring more clinical treatment options to patients with malignant tumors.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 28 November 2023

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.